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Background: Coronary artery calciﬁcation (CAC) is a well-established risk factor for the occurrence of adverse
ischemic events. However, the economic impact of the presence of CAC is unknown.
Objectives: Through an economic model analysis, we sought to estimate the incremental impact of CAC on
medical care costs and patient mortality for de novo percutaneous coronary intervention (PCI) patients in the
2012 cohort of the Medicare elderly (≥65) population.
Methods: This aggregate burden-of-illness study is incidence-based, focusing on cost and survival outcomes for
an annual Medicare cohort based on the recently introduced ICD9 code for CAC. The cost analysis uses a one-
year horizon, and the survival analysis considers lost life years and their economic value.
Results: For calendar year 2012, an estimated 200,945 index (de novo) PCI procedures were performed in this co-
hort. An estimated 16,000Medicare beneﬁciaries (7.9%)were projected to have had severe CAC, generating an ad-
ditional cost in the ﬁrst year following their PCI of $3500, on average, or $56million in total. In terms of mortality,
the model projects that an additional 397 deaths would be attributable to severe CAC in 2012, resulting in 3770
lost life years, representing an estimated loss of about $377million, when valuing lost life years at $100,000 each.
Conclusions: These model-based CAC estimates, considering both moderate and severe CAC patients, suggest an
annual burden of illness approaching $1.3 billion in this PCI cohort. The potential clinical and cost consequences
of CAC warrant additional clinical and economic attention not only on PCI strategies for particular patients but
also on reporting and coding to achieve better evidence-based decision-making.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery calciﬁcation (CAC) is both an established risk factor
for poor cardiovascular clinical outcomes and a predictor of additional
resource utilization and overall health care costs [1–5]. Although most
percutaneous coronary intervention (PCI) trials have excluded patients
with eithermoderately- or severely-calciﬁed coronary lesions, Genereuxascular Systems, Inc., 1225 Old
oung, Philippe Généreux, Janna
from Cardiovascular Systems,
oup, Inc.
s Research & Policy Program,
30, Seattle, WA 98195. Tel.: +1
. This is an open access article underand colleagues’ recent analysis of pooled data from the HORIZONS-AMI
[6] and ACUITY [7] trials demonstrates that patients with moderate and
severe coronary calciﬁcation experience worse ischemic outcomes –
stent thrombosis, target lesion revascularization (TLR), and mortality –
after PCI compared to patients with no CAC [4].
Less is known about the population-level burden of coronary calciﬁ-
cation. Prior to 2011, clinically signiﬁcant CAC lacked a speciﬁc ICD9
diagnosis code, an important administrative data element needed for
conducting a population-level, epidemiologically-based analysis. Al-
though a new diagnostic code (ICD9 414.4 for coronary calciﬁcation)
was introduced late in 2011, actual documentation of CAC via adminis-
trative coding practice has lagged. This is the ﬁrst published analysis to
examine the reporting and use of this ICD9 code and to assess the cli-
nical and cost burden of calciﬁcation in de novo PCI patients in the elder-
ly (age 65 and older) Medicare population. In addition, we estimated
the economic burden of CAC in this select Medicare PCI population inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic diagramof the economicburdenmodel. The aggregate burden of illness is
theproduct of PCI incidence, the severity of calciﬁcation, and thepatient outcomes in terms
of costs and outcomes. Abbreviations: CAD = coronary artery disease, Dx = diagnosis,
PCI = percutaneous coronary intervention, CABG= coronary bypass graft.
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impact of CAC – at both the PCI patient-level and in the aggregate – on
associated medical care costs and patient mortality in the 2012 cohort
of the Medicare elderly population?
2. Methods
2.1. Study design
The target study population was the Medicare elderly with athero-
sclerosis in calendar year 2012 experiencing a new (de novo) index
PCI, deﬁned as a patient receiving a coronary angiogram with no prior
coronary revascularization in the preceding six months. This was an ag-
gregate, population-level economic burden study, which is also known
as a “cost-of-illness” or “burden-of-disease” study [8,9]. The study de-
sign was incidence-based, focusing on cost and survival outcomes for
an annual cohort of the target study population. The horizon of the
cost analysis was one year because the greatest cost impact tends to
occur in the ﬁrst year post-procedure, and due to the limited data for
these patients. The horizon for survival analysis was a patient’s lifetime,
given that mortality differences at one year can bemodeled as life years
lost over the remaining expected lifetime.
CAC could potentially adversely affect patients’ clinical outcomes for
those who underwent PCI, coronary artery bypass graft surgery (CABG),
or prescribed medical therapy for severe atherosclerosis deemed not
treatable via surgical intervention.Of coronary angiographypatientswith-
out a revascularization in the last 6 months, 5% underwent CABG (3.1%
documented calciﬁcation), 31% underwent PCI (1.9% documented calciﬁ-
cation), and 64% underwent a medical intervention (1.5% documented
calciﬁcation). However, the focus of this analysiswas onpatients receiving
PCI, due to the limited number of CABG and medical therapy patients
documented with the calciﬁcation code in the available Medicare data.
The study design and analysis were inﬂuenced by the availability of
CAC data. A new diagnostic code for calciﬁcation (ICD9 414.4) was in-
troduced in the last quarter of 2011. Because the reporting of new
codes can take time to become a part of regularmedical documentation
practice, there is a high likelihood of under-reporting of CAC in this ini-
tial period. This limited reporting affected the ability to do a strict
epidemiologically-based comparison of patientswith reported calciﬁca-
tion versus thosewith non-calciﬁed coronary lesions, given that such an
approach would be subject to misclassiﬁcation bias in which many
patients with severe calciﬁcation would be inappropriately classiﬁed
in the non-CAC group. Therefore, an aggregate estimate was constructed
using an economic modeling approach that synthesizes data frommulti-
ple sources described below.
The principal data sources for cost and survival analyses wereMedi-
care’s Standard Analytic Files (SAFs). The SAFs comprise seven data sets
containing detailed claims information about health care services ren-
dered to Medicare beneﬁciaries in fee-for-service (FFS) Medicare. SAFs
are available for institutional (inpatient, outpatient, skilled nursing faci-
lity, hospice, or home health agency) and non-institutional (physician
and durable medical equipment providers) claim types. Data are orga-
nized at the claim level and include basic beneﬁciary demographic in-
formation, date of service, diagnosis and procedure code, provider
number, and reimbursement amount. Two SAF databases were used:
the Medicare 5% random sample SAF and 100% SAF. The 5% sample of
beneﬁciaries includes all of their claims (inpatient, outpatient, physi-
cian, durable medical equipment, etc.) except drugs, which are tracked
and reported separately viaMedicare Part D. The100%SAF includes only
inpatient and outpatient claims but includes all FFS beneﬁciaries. In
addition, a special sub-sample was deﬁned from the 100% SAF that
included all hospitals (n = 17) that coded more than 10% of their PCI
patients as having CAC (using code 414.4).
The Medicare SAF analyses were conducted with Limited Data Set
(LDS)ﬁles, which encrypt beneﬁciary identiﬁers, and this research com-
plies with the Centers for Medicare and Medicaid Services Data UseAgreement rules on blinding and data use. Institutional Review Board
approval is not required for use of LDS administrative data under the
HIPAA Privacy Rule.
To better estimate the degree of calciﬁcation and incidence of major
adverse cardiovascular events among this target patient group, addi-
tional data from the HORIZONS-AMI/ACUITY pooled sample were
used, though this dataset does not contain information on costs [4]. Ap-
proval for analyses of this pooled sample was obtained from the Institu-
tional ReviewBoards or Ethics Committees at each of the enrolling sites.
2.2. Economic model: cost burden of coronary calciﬁcation
A population-level economic model was constructed drawing
parameter estimates fromboth a detailed analysis of the availableMedi-
care claimsdata and from the published literature. Amodeling approach
also allowed for assessing the sensitivity of the results to varying
assumptions about key parameters.
As depicted in Fig. 1, the economic model had three major compo-
nents: 1) the estimated annual incidence of elderly Medicare patients
receiving an index PCI (typically a drug-eluting stent); 2) the incidence
of CAC in these PCI patients, classiﬁed as severe, moderate, or mild/
none; and 3) the estimated impact of the three levels of CAC on Medi-
care per-patient costs and health outcomes (viz., mortality).
2.3. Incidence of PCI in 2012
The 100% Medicare SAFs of administrative claims data were used to
deﬁne the index population in 2012,which includes only patients in the
Medicare FFS population. The cohort was restricted to elderly patients
(i.e., age 65 or older). Although Medicare Advantage (MA) patients
represented about 21.7% of theMedicare population in 2012- and rising
substantially annually – these data are not included in this database. To
account forMApatients,wemade a simple, crude adjustment, increasing
the aggregate burden estimate for the whole population upward to
reﬂect the inclusion of this subpopulation.
2.4. Incidence of calciﬁcation in the elderly
We reported incidence of CAC in the Medicare population based on
the 414.4 code. However, given the likely under-reporting of CAC in
the 2012 Medicare SAF cohort, the estimated incidence of moderate
and severe CAC was based on estimates from the HORIZONS-AMI/
ACUITY pooled sample [4]. The estimatedmeans for the elderly subsam-
ple were used in the base case. The range for the assumption was based
on the literature [5,10]. Calciﬁcation incidence from the HORIZONS-
Table 1
Baseline characteristics of Medicare patients with and without coronary artery
calciﬁcation.
Characteristic CAC No CAC Total
Age 65–74
Male
n 825 65,193 66,018
Mean Charlson Score (SD) 2.5 (2.3) 2.1 (2.2) 2.1 (2.2)
95% CI 2.1–2.3 2.0–2.1
Mean Age (SD) 69 (3) 69 (3) 69 (3)
95% CI 69–70 69–69
Female
n 427 34,874 35,301
Mean Charlson Score (SD) 2.5 (2.4) 2.3 (2.3) 2.3 (2.3)
95% CI 2.3–2.7 2.3–2.3
Mean Age (SD) 70 (3) 70 (3) 70 (3)
95% CI 69–70 70–70
Age 75–84
Male
n 393 25,399 25,792
Mean Charlson Score (SD) 2.8 (2.5) 2.4 (2.3) 2.4 (2.3)
95% CI 2.5–3.0 2.4–2.5
Mean Age (SD) 79 (3) 79 (3) 79 (3)
95% CI 79–79 79–79
Female
n 267 18,798 19,065
Mean Charlson Score (SD) 2.7 (2.4) 2.3 (2.2) 2.3 (2.2)
95% CI 2.5–3.0 2.3–2.3
Mean Age (SD) 79 (3) 79 (3) 79 (3)
95% CI 79–80 79–79
Age 85+
Male
n 92 5392 5484
Mean Charlson Score (SD) 3.1 (2.5) 2.7 (2.3) 2.7 (2.3)
95% CI 2.6–3.6 2.6–2.8
Mean Age (SD) 87 (2) 87 (2) 87 (2)
95% CI 87–88 87–87
Female
n 80 5600 5680
Mean Charlson Score (SD) 2.7 (2.1) 2.3 (2.1) 2.3 (2.0)
95% CI 2.3–3.2 2.2–2.3
Mean Age (SD) 88 (3) 88 (3) 88 (3)
95% CI 87–88 88–88
Values are based on authors’ analysis of the Medicare 100% Standard Analytic File for 2012.
Presents descriptive data on subgroup characteristics. Abbreviations: CAC = Coronary Ar-
tery Calciﬁcation, CI = Conﬁdence Interval, SD = Standard Deviation.
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determine population size for CAC.
2.5. Medical care cost impact
Estimation of the ﬁrst-year impact of calciﬁcation following index
PCI on costs was based on a generalized estimating equation (GEE) re-
gression analysis of data from the Medicare 5% Standard SAFs, which
were used because they contain the most complete cost data including
physician claims—adjusting for age, gender, and the Charlson comorbi-
dity index [11]. The Charlson index was used rather than individual co-
morbidities to decrease the effect of correlation and increase power of
the models. As previously noted, an adjustment for the MA patients
was applied in the aggregate population model. In the aforementioned
available data, approximately 20% of patients had one-year of follow-
up data. Techniques developed by Lin et al. [12] and Basu et al. [13]
were applied to address censoring in order to fully utilize patient cost
data up to the point of loss-to-follow-up or death.
2.6. Mortality impact
We reported the impact of CAC on mortality using the 100% Medi-
care SAF. However, given the likely under-reporting of CAC in the
2012Medicare SAF cohort, the estimated mortality impact of moderate
and severe CAC was based on new tabulations from the HORIZONS-
AMI/ACUITY pooled sample, an in-depth analysis of cardiac death in
the sample studied by Genereux et al. [4]. Cardiac death was used, as
all causes of mortality were not available and cardiac death was as-
sumed to be most relevant. A Cox proportional hazards model was
used to account for censoring with adjustment for age, gender, the
Charlson comorbidity index, and the comorbidities end-stage renal dis-
ease and diabetes, which were included explicitly in order to evaluate
their speciﬁc effects due to their potential key role in the causal frame-
work. The impact of the mortality differential on the health outcomes
for the 2012 cohort was assessed both in terms of lost life-years and
the associated monetized value of those lost life-years. For the life ex-
pectancy calculation, the estimate of lost life yearswas based on theme-
dian age and gender of an elderly PCI patient (i.e., a 74-year-old male)
who would normally have an expected lifetime of 11.5 years: this was
then adjusted down to 9.5 years after standard discounting at 3% per
annum. A sensitivity analysis scenario used a mortality differential
25% higher than the base case as a ‘high case’ for mortality, and a ‘low
case’ sensitivity analysis conservatively assumed no survival difference
between CAC and non-CAC PCI patients.
2.7. Aggregate burden-of-illness model
In order to assess the overall burden of CAC, we aimed to include
both true economic costs aswell as the effects on health. Fig. 1 illustrates
how the economic model of the burden of illness integrated each of the
components above to produce an aggregate estimate of the economic
burden. The ﬁrst component was the incidence of PCI by age and
gender. The second component represented the degree of CAC within
these age and gender groups.
The third component was patient outcomes with two dimensions:
cost andmortality impacts,whichwere included in themodel in two ca-
pacities. First, the attributedmedical cost burdenwas the product of the
number of patients with CAC and the expected average attributable an-
nual cost for patients in the 2012 cohort receiving an index PCI proce-
dure. Second, to combine health and economic effects, we converted
health impact into a monetary value. We utilized a method valuing
life-years according to willingness-to-pay thresholds, as discussed in
the recently published ACC/AHA Task Force on value and cost in guide-
line development [14]. For example, if the societal willingness-to-pay
for one year of healthy life is $100,000, we valued a year of healthy sur-
vival in themodel at that amount. In this waywe could report a singulareconomic impact rather than separate economic and health impacts.
The willingness-to-pay threshold has the limitations both of being sub-
ject to societal acceptance, as well as being difﬁcult to estimate with a
high degree of certainty. Accordingly, we varied the willingness-to-
pay threshold at three levels in order to address societal uncertainties
in the threshold. Estimates of societal willingness to pay for life year
gains were based on the Andersen et al. thresholds for “levels of
value”—high, medium, and low [14]: the base case assumed $100,000
per life year gained, while the lower bound was $50,000 and the
upper bound was $150,000.
For all inputs, the model was evaluated at a base case, based on the
results of the analyses, and at low and high values in the scenario
sensitivity analyses based on the expert judgment of the co-authors as
to the degree of uncertainty and plausible variation.
3. Results
3.1. Incidence of index PCI—Medicare cohort
Based on the analysis for the Medicare 100% SAF for calendar year
2012, there were 157,340 index PCI procedures performed, which
amounted to an estimated 200,945 when adjusted for the MA patients.
Table 1 shows mean Charlson comorbidity scores and ages by gender.
The mean age was 73.4 years, 61.8% were males, and 66.4% were
between ages 65 and 74.
Table 2
Coronary calciﬁcation rates by age.
Medicare Patients with
CAC from SAFa
Genereux et al. estimates for calciﬁcation
prevalence in the PCI populationb
Adjusted calciﬁcation prevalence
in the Medicare Population (n)
Moderate Coronary Calciﬁcation
65–74 N/A 30.0% 30,396
75–84 N/A 34.0% 15,251
85+ N/A 28.6% 3193
Total N/A – 48,840 (31.0%)
Severe Coronary Calciﬁcation
65–74 1252
(1.2%, 95% CI 1.1–1.3)
7.2% 7295
75–84 660
(1.5%, 95% CI 1.4–1.6)
8.8% 3947
85+ 172
(1.5%, 95% CI 1.3–1.8)
10.5% 1172
Total 2084
(1.3%, 95% CI 1.3–1.4)
– 12,414 (7.9%)
Comparison of age-speciﬁc coronary calciﬁcation rates by age group and severity level. Abbreviations: CAC = coronary artery calciﬁcation, CI = Conﬁdence Interval, PCI = Percutaneous
Coronary Intervention, SAF = Standard Analytic Files.
a ICD9 code 414.4.
b These estimates are based on new tabulations from HORIZONS-AMI/ACUITY pooled sample, as described in Genereux et al. (2014) (Data on ﬁle, Cardiovascular Research Foundation,
New York, NY, USA).
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We estimated that, in the 2012 Medicare SAF data, 1.3% of index PCI
and CABG patients were coded as having CAC (Table 2). When com-
pared with estimates from the HORIZONS-AMI/ACUITY pooled analysis
of 5.9% severe CAC and 26.1% moderate CAC in a PCI patient population
with amean age of 65 [4], under-reporting seems highly likely. The base
case estimates were weighted by the age distribution of the Medicare
population (data on ﬁle at Cardiovascular Research Foundation, New
York, NY, USA) and projected to be 7.9% for severe and 31% formoderate
CAC based on a tabulation using HORIZONS-AMI/ACUITY pooled data
for the elderly (Table 2). For comparison, within the sub-sample of hos-
pitals that coded more than 10% of their PCI patients as having CAC
using code 414.4 (n= 17), 14.1% of PCI patients were coded as calciﬁed
in 2012.
3.3. Medical cost impact
Based on the adjusted GEE analysis in the Medicare 5% SAF data, el-
derly PCI patients without CAC incurred an average of $16,800 in costs
at the time of index event and a total of $24,700 in the ﬁrst year, and
those with severe CAC incurred an additional $800 in costs at the time
of index event for a total of $3500 in additional costs (Table 3) in the
ﬁrst year following the procedure [15]. Based on the assumed 50%Table 3





Incremental Cost of Calciﬁcation
Unadjusted Adjusted for age, gender,
and censored costs using
Lin et al. method)
Time Period
Index $16,800 $1300 $800
1–30 days $1700 $1100 $400
31–90 days $2200 $500 $1050
91–180 days $2350 $650 $350
181–270 days $1100 $550 $550
271–360 days $550 $1800 $350
Total $24,700 $5900 $3500
Comparison of costs by period for Medicare 5% SAF patients with reported calciﬁcation
(n = 221 at index; n = 88 at 360 days) and without reported coronary calciﬁcation
(n = 11,489 at index; n = 4660 at 360 days), with adjustments for covariates and
censoring.differential, the base case patient with moderate CAC incurs $1750 in
costs, on average.
3.4. Survival impact
Based on the 100%Medicare SAF, the one-year hazard ratio for mor-
tality for patients with CAC compared to no CACwas 1.08 (9.30%morta-
lity at 1-year vs. 8.6% without CAC), but was not statistically signiﬁcant
at the p= 0.05 level without adjustments for sample differences in age,
gender, or the Charlson comorbidities index. The inclusion of comorbi-
dities, such as diabetes and end-stage renal disease, further minimized
the effect of CAC. New tabulations using the HORIZONS-AMI/ACUITY
pooled sample estimated that one-year cardiac mortality in patients
with severe CAC was 5.8%, in patients with moderate CAC was 4.5%,
and in patients with no or mild CAC was 3.3% (data on ﬁle at Cardiovas-
cular Research Foundation, New York, NY, USA); resulting in an
observed 1.2% differential in 1-year mortality between moderate CAC
and no/mild CAC, and a 2.5% differential between severe CAC and no/
mild CAC. These differentials were used as inputs in the aggregate
burden model below.
3.5. Aggregate burden
Table 4 summarizes the input assumptions for the aggregate burden
in the base case analysis for index PCI patients in 2012, and Table 5 sum-
marizes the results. Of the 2012 cohort of index PCI patients, 15,875
Medicare beneﬁciaries (7.9%) were projected to have had severe CAC.
Based on the estimate of an additional $3500 per patient in the ﬁrst
year following their PCI, these patients were projected to generate an
additional $55.6 million in total. The impact on survival (based on
these estimates) of patients with severe CAC can be attributed to an
additional 397 deaths in 2012, resulting in 3770 lost life years, which
when monetized in the base case would represent an estimated loss
of about $377 million.
Of the 2012 cohort of index PCI patients, 62,896Medicare beneﬁcia-
ries (31%) were projected to have hadmoderate CAC. Based on the esti-
mate of an additional $1750 per patient in the ﬁrst year following their
PCI, these patients were projected to generate an additional $110
million in medical care costs. This result is driven by the much larger
number of patients projected to have had moderately-calciﬁed lesions.
In total for 2012, in the base case, the estimated medical cost burden
was $166 million and the monetized mortality burden was $1.1 billion
for a total of $1.3 billion for this cohort (Fig. 2).
Table 4
Model inputs.
Low Base High Source
Annual Incidence
PCI 157,340 157,340 157,340 Medicare 100% SAF estimates
Adjustment for Medicare Advantage 21.70% 21.70% 21.70% Medicare Program Statistics
Total 200,945 200,945 200,945 Calculated (PCI/MA Adjustment)
Coronary Calciﬁcation
Percentage Severe 6% 8% 10% Assumption based on [4]
Percentage Moderate 26% 31% 35% Assumption based on [4]
Annual Cost Impact
PCI: Moderate Calciﬁcation $1250 $1750 $3750 Assumption
PCI: Severe Calciﬁcation $2500 $3500 $7500 Medicare 5% SAF
Annual Mortality Impact
PCI: Moderate Calciﬁcation 0 0.012 0.015 Authors’ calculation
PCI: Severe Calciﬁcation 0 0.025 0.031 Authors’ calculation
Other
Patient Age 73.4 73.4 73.4 Cohort Mean in Medicare 100% SAF
Mean Remaining Life Expectancy 8 9.5 11 US Life Tables (in years)
Value of Lost Life Year $50,000 $100,000 $150,000 Assumptions based on [14].
Summary of values and ranges for all variables in the economic burden calculation. Abbreviations: MA = Medicare Advantage, PCI = percutaneous coronary intervention,




Estimated 2012 PCI Incidence 200,945 200,945 200,945
Severe Coronary Calciﬁcation
Cost
Projected Incidence 12,057 15,875 20,095
Estimated Incremental Per Patient Cost $2500 $3500 $7500
Projected Aggregate Medical Cost (000s) $30,142 $55,561 $150,709
Mortality
Estimated Incremental Deaths 0 397 628
Projected Total Life Years Lost 0 3770 6907
Aggregate Monetized Mortality Burden
(000s)
0 $377,023 $1,036,123
Severe: Total Economic Burden (000s) $30,142 $432,585 $1,186,832
Moderate Coronary Calciﬁcation
Cost
Projected Incidence 52,447 62,896 70,331
Estimated Incremental Per Patient Cost $1250 $1750 $3750
Projected Aggregate Medical Cost (000s) $65,558 $110,068 $263,740
Mortality
Estimated Incremental Deaths 0 755 1055
Projected Total Life Years Lost 0 7170 11,605
Aggregate Monetized Mortality Burden
(000s)
0 $717,012 $1,740,687
Moderate: Total Economic Burden (000s) $65,558 $827,080 $2,004,427
Grand Totals
Total Medical Cost Burden (000s) $95,700 $165,629 $414,449
Total Monetized Mortality Burden (000s) $0 $1,094,035 $2,776,810
Total Economic Burden (000s) $95,700 $1,259,664 $3,191,259
Summary of results for burden of illness for three scenarios with alternative sets of base
case, lower burden, and higher burden assumptions. Abbreviations: PCI = percutaneous
coronary intervention.
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highly sensitive to the assumptions about the impact of CAC on morta-
lity. If patients with CAC did not experience any additional mortality,
then the medical cost alone would be $95 million in the low-cost sce-
nario and $414 million in the high-cost medical scenario. If, however,
lost life-years are valued at $150,000 per life year, then the economic
burden would be greatly multiplied to over $3 billion for this cohort
with moderate or severe CAC in 2012.
4. Discussion
To the best of our knowledge, this analysis represents the ﬁrst esti-
mate of the societal burden of illness due to CAC in the U.S. The aggre-
gate economic burden is substantial, estimated to be over $1 billion in
the base case, and up to as much as $3 billion. The burden of illness is
much greater when CAC is associated with greater post-PCI morbidity
and mortality. Given the lagging documentation of the recently intro-
duced new ICD9 code for coronary calciﬁcation (414.4), onemightwon-
der if this attempt to quantify the burden of CAC is premature. Studying
the early experience of the use of this code for CAC in theMedicare pro-
gramhighlights the challenges in conducting this kind of analysis. In the
future, more reﬁned estimates should be possible, based onmore accu-
rate assessments of prevalence of CAC. However, clinical and economic
policy decisions are being made – even if implicit – and they cannot
necessarily wait for complete or perfect data.
Based on this analysis, CAC is substantially under-reported in the el-
derly Medicare population, particularly when one appreciates the rela-
tionship between advanced age and CAC [4]. Inadequate medical
coding of CAC – and likely incomplete medical record documentation
of it – also raises concerns about clinician awareness and management
of this important element of comorbidity, which is often associated
with chronic conditions including advanced age, diabetes mellitus,
renal insufﬁciency, and hypertension [16,17]. Even so, our estimates
project that CAC generates a large economic burden in the elderlyMedi-
care population—and perhaps in younger cohorts.
The recent call by the ACC/AHA for the greater use of economic data
in guideline development underscores the point that formulating ap-
propriate treatment guidelines depends on the availability of clinical
and claims data in which CAC is deﬁned in relevant clinical terms that
enable appropriate consistent measurement and reporting [14]. Findings
such as these also should have implications for curriculum and training
programs for interventional cardiology fellows.
Most analyses in the health economics and outcomes research lite-
rature are assessments of either short-term costs or comparative cost-
effectiveness of various treatment options. Payers are increasinglyinterested in the comparative costs aswell as the clinical beneﬁts of var-
ious therapeutic options. Why should we be concerned about the
burden of illness for CAC at a societal level? PCI revascularization tech-
nologies now are being developed for improved revascularization stra-
tegies in patients with CAC that may positively impact both clinical
outcomes along with the cost burden of CAC [18–20]. Since societal
costs are estimated to be signiﬁcant, comparative clinical and economic
evaluations of potential improved therapeutic approaches to the
management of patients with CAC should be pursued.
4.1. Limitations
This study had several key limitations. First, given the apparent low
reporting of CAC in the claims we examined, a standard epidemiologic
cohort analysis comparing the costs of patients with and without CAC
Fig. 2. Aggregate economic burden by degree of coronary calciﬁcation. This compares themonetized aggregate burden due tomoderate vs. severe coronary calciﬁcation, the former being
larger due to the greater incidence.
411L.P. Garrison Jr. et al. / Cardiovascular Revascularization Medicine 16 (2015) 406–412would be subject to misclassiﬁcation bias: the comparison groupwould
be contaminated by patients who actually have CAC. There is no easy or
certain way to remove this bias from such an analysis.
Second, a lifetime horizon is preferable to a one-year time horizon
for both costs and outcomes; however, no data on cost or mortality dif-
ferences after year one were available. We assume that patients with
CAC would have lower life expectancy and would likely require greater
utilization and costs. Thus, our assumptions are conservative in terms of
overall burden. Additionally, due to the small sample size, as well as
having access only to aggregate data rather than individual patients
for the Medicare data, we cannot report rates based on very small
numbers of patients, such as repeat PCI and/or bypass surgery for
these patients in the follow-up one-year phase, which would be an
important and interesting result.
Third, since the 414.4 code for calciﬁcation is early in its adoption
into standard documentation and clinical practice, it is plausible thatFig. 3. Sensitivity of the economic burden results based on alternativemortality scenarios (low,
about mortality and cost impact.the code was used more frequently in cases where calciﬁcation was
particularly evident or important for the patient’s treatment plan. If
any misclassiﬁcation bias did occur, it would likely bias our overall
burden estimate downward.
Additionally, basing life expectancy of patients with or without CAC
on standard U.S. life tables ignores the effect of cardiovascular disease
on life expectancy, and assumes that patients with or without CAC
have similarmortality risk.We chose tomake this conservative assump-
tion, sincewe do not have the ability as yet to effectively stratify the CAC
population within existing mortality data for cardiovascular disease.
There are likely othermechanisms that affect survival aswell, speciﬁcal-
ly myocardial infarction or other revascularizations. For this analysis,
data on other mechanisms were not available. We assume that, if
anything, the survival outcomes for CAC patients would be worse
when additional factors are included. Therefore, our results represent
a conservative estimate for burden of the disease.base, and high). The aggregate economic burden varies widely, depending on assumptions
412 L.P. Garrison Jr. et al. / Cardiovascular Revascularization Medicine 16 (2015) 406–412Finally, the model focuses on the PCI patient population receiving
stents, due to (1) the lack of data on index CABG with CAC in the 5%
SAF (fewer than 50 patients); and (2) the inability to measure cost im-
pacts on patients with moderate or severe CAC receiving medical ther-
apy. The incidence of PCI in the 100% SAF may seem low compared to
other PCI annual volume estimates in the literature, but these other es-
timates also include repeat PCIs, patients under the age of 65, and those
enrolled in MA. Our Medicare SAF-based estimates suggest that the
average cost of CABG is more than twice that of PCI. Other trials –
such as the SYNTAX trial [21] – have suggested that CAC can be a reason
for the use of (higher cost) CABG rather than lower cost PCI. Further-
more, some patients with severe CAC are likely to be treated medically
and not even considered for revascularization, and some of these pa-
tients will die before becoming candidates for revascularization. All of
these would generate additional burden that is not measured here.
Hence, the estimated economic burden, based only on index PCIs, is
likely to be conservative.
5. Conclusions
While there is clear evidence that the degree of CAC complicates the
treatment of CAD, there has been little, if any, previous effort to assess
its related economic burden. Analyses relying on aggregate administra-
tive claims alone have been hampered by the lack of routine medical
coding for CAC, which results in substantial under-reporting and
makes epidemiologic and economic analyses challenging and potential-
ly biased. Despite these limitations, a plausible and conservative eco-
nomic model was constructed. In the base case, the economic burden
in one annual elderly cohort alone is estimated to be $1.3 billion. Al-
though the potential bias and sample size limitations have been noted,
the results demonstrate conservatively the signiﬁcant economic burden
of calciﬁcation in the population. Although the data available to address
the burden of CAC are neither complete nor ideal, it is clearly a signiﬁ-
cant clinical and economic issue, and this analysis is an important ﬁrst
step to pave the way for future work. At a minimum, this analysis sug-
gests the need for ongoing, periodic reviews to assess the prevalence
of CAC in the Medicare population.
Clinical guidelines and economic policies both need to be grounded in
reliable evidence to promote substantial health improvement and to seize
appropriate cost containment opportunities. Professional medical and
other clinical societies should consider initiating amember education cam-
paignon thenewstandards for appropriate codingof CAC.A greater appre-
ciation of the potential consequences for CAC is warranted, arguing for
greater attention not only to its treatment but also its reporting and coding
in order to support better evidence-based decision-making in this area.
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